Compare Ecolab Inc. (ECL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Ecolab Inc. trades at $273.58 (market cap $76.06B), while State Street SPDR S&P Biotech ETF trades at $151.17. The key difference: Ecolab Inc. pays a 1.08% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Ecolab Inc. nearer its low. Which is the better fit depends on your goals.
| ECL | XBI | |
|---|---|---|
Market Cap | $76.06B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $308.35 | $164.28 |
52-Week Low | $245.73 | $85.16 |
Enterprise Value | $84.81B | — |
Dividend Yield | 1.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $273.62, up 1.43% with a bearish technical signal despite strong analyst support. The company shows solid fundamentals with $16.08B revenue, 12.8% net margin, and 22.31% ROE. Recent Q1 2026 earnings met expectations while Q2 2026 results are pending. The $4.75B CoolIT acquisition strengthens AI cooling capabilities, positioning for long-term growth in high-tech markets.
ECL presents a compelling growth story with improving profitability and strategic acquisitions, though current valuation multiples appear elevated. Key risks include execution of recent acquisitions and rising cost pressures. With 76% analyst buy ratings and a $327.43 consensus target suggesting 20% upside, the stock offers potential for patient investors despite near-term technical weakness.
XBI (SPDR S&P Biotech ETF) trades at $152.07, down 2.23% today, but maintains a bullish technical outlook with strong momentum indicators. The ETF has gained significant attention with a 17% monthly surge, driven by biotech sector strength and increased M&A activity. Analyst coverage shows a cautious stance with 100% hold rating, reflecting balanced risk-reward assessment amid sector volatility.
The biotech sector shows strong momentum with AI drug discovery advances and record M&A activity ($106 billion in 2026). While XBI offers high-beta exposure to small/mid-cap biotech growth, investors face elevated volatility and regulatory uncertainties. The equal-weight portfolio structure provides diversified exposure to sector innovation but requires tolerance for price swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
